3.00
price down icon1.64%   -0.05
after-market After Hours: 3.00
loading
Neumora Therapeutics Inc stock is traded at $3.00, with a volume of 810.22K. It is down -1.64% in the last 24 hours and up +53.06% over the past month. Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
See More
Previous Close:
$3.05
Open:
$3.09
24h Volume:
810.22K
Relative Volume:
0.52
Market Cap:
$509.82M
Revenue:
-
Net Income/Loss:
$-236.30M
P/E Ratio:
-2.0502
EPS:
-1.4633
Net Cash Flow:
$-208.07M
1W Performance:
-15.49%
1M Performance:
+53.06%
6M Performance:
+78.57%
1Y Performance:
+109.79%
1-Day Range:
Value
$2.915
$3.09
1-Week Range:
Value
$2.76
$3.60
52-Week Range:
Value
$0.611
$3.65

Neumora Therapeutics Inc Stock (NMRA) Company Profile

Name
Name
Neumora Therapeutics Inc
Name
Phone
(857) 760-0900
Name
Address
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Name
Employee
95
Name
Twitter
Name
Next Earnings Date
2026-03-03
Name
Latest SEC Filings
Name
NMRA's Discussions on Twitter

Compare NMRA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
NMRA
Neumora Therapeutics Inc
3.00 518.31M 0 -236.30M -208.07M -1.4633
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
460.82 121.40B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
764.93 83.25B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
728.11 46.39B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.51 43.41B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
292.94 33.09B 5.36B 287.73M 924.18M 2.5229

Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-17-26 Upgrade William Blair Mkt Perform → Outperform
Jan-12-26 Initiated Leerink Partners Outperform
Dec-01-25 Upgrade RBC Capital Mkts Sector Perform → Outperform
Oct-27-25 Upgrade Guggenheim Neutral → Buy
Sep-16-25 Downgrade JP Morgan Neutral → Underweight
Apr-02-25 Downgrade BofA Securities Buy → Underperform
Mar-10-25 Downgrade William Blair Outperform → Mkt Perform
Mar-07-25 Downgrade Guggenheim Buy → Neutral
Mar-07-25 Downgrade Stifel Buy → Hold
Jan-02-25 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-05-24 Downgrade JP Morgan Overweight → Neutral
Oct-01-24 Initiated H.C. Wainwright Buy
Jul-22-24 Initiated Needham Buy
Jul-08-24 Initiated Mizuho Outperform
Dec-12-23 Initiated Deutsche Bank Hold
Oct-10-23 Initiated BofA Securities Buy
Oct-10-23 Initiated Guggenheim Buy
Oct-10-23 Initiated JP Morgan Overweight
Oct-10-23 Initiated RBC Capital Mkts Outperform
Oct-10-23 Initiated Stifel Buy
Oct-10-23 Initiated William Blair Outperform
View All

Neumora Therapeutics Inc Stock (NMRA) Latest News

pulisher
Mar 04, 2026

Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511 - Finviz

Mar 04, 2026
pulisher
Mar 04, 2026

Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements - Bitget

Mar 04, 2026
pulisher
Mar 03, 2026

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

Mar 03, 2026
pulisher
Mar 03, 2026

12 Best NASDAQ Penny Stocks to Buy According to Analysts - Insider Monkey

Mar 03, 2026
pulisher
Mar 02, 2026

Neumora Therapeutics (NASDAQ:NMRA) Shares Gap DownTime to Sell? - MarketBeat

Mar 02, 2026
pulisher
Mar 02, 2026

GSA Capital Partners LLP Cuts Position in Neumora Therapeutics, Inc. $NMRA - MarketBeat

Mar 02, 2026
pulisher
Feb 27, 2026

AlphaCore Capital LLC Has $1.16 Million Stock Holdings in Neumora Therapeutics, Inc. $NMRA - MarketBeat

Feb 27, 2026
pulisher
Feb 23, 2026

Neumora Therapeutics (NMRA) Projected to Post Earnings on Monday - MarketBeat

Feb 23, 2026
pulisher
Feb 21, 2026

Neumora cut to Hold at Stifel after J&J’s VENTURA exit - MSN

Feb 21, 2026
pulisher
Feb 21, 2026

Can Neumora Therapeutics Inc. stock withstand economic slowdownJuly 2025 Snapshot & Weekly Setup with High ROI Potential - mfd.ru

Feb 21, 2026
pulisher
Feb 21, 2026

Risk Recap: Is Telomir Pharmaceuticals Inc stock a buy or sellFed Meeting & Smart Allocation Stock Tips - baoquankhu1.vn

Feb 21, 2026
pulisher
Feb 20, 2026

Neumora Therapeutics CFO Milligan sells $5119 in shares By Investing.com - Investing.com Australia

Feb 20, 2026
pulisher
Feb 20, 2026

Neumora Therapeutics CFO Milligan sells $5119 in shares - Investing.com South Africa

Feb 20, 2026
pulisher
Feb 19, 2026

Top Neumora Executives Quietly Cash Out in Coordinated Stock Sell-Off - TipRanks

Feb 19, 2026
pulisher
Feb 19, 2026

Insider Sell Alert: Michael Milligan Sells Shares of Neumora The - GuruFocus

Feb 19, 2026
pulisher
Feb 19, 2026

Neumora Therapeutics (NASDAQ:NMRA) Insider Paul Berns Sells 9,819 Shares - MarketBeat

Feb 19, 2026
pulisher
Feb 19, 2026

Insider Selling: Neumora Therapeutics (NASDAQ:NMRA) Insider Sells 6,165 Shares of Stock - MarketBeat

Feb 19, 2026
pulisher
Feb 18, 2026

Trading Recap: Will Neumora Therapeutics Inc stock go up in YEARTake Profit & Fast Exit Strategy with Risk Control - baoquankhu1.vn

Feb 18, 2026
pulisher
Feb 18, 2026

Neumora Therapeutics advances in novel brain-penetrant therapies - Traders Union

Feb 18, 2026
pulisher
Feb 18, 2026

Neumora Therapeutics (NASDAQ:NMRA) Hits New 12-Month High Following Analyst Upgrade - MarketBeat

Feb 18, 2026
pulisher
Feb 17, 2026

William Blair upgrades Neumora Therapeutics (NMRA) - MSN

Feb 17, 2026
pulisher
Feb 17, 2026

William Blair Upgrades Neumora Therapeutics (NMRA) - Nasdaq

Feb 17, 2026
pulisher
Feb 17, 2026

Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment - Benzinga

Feb 17, 2026
pulisher
Feb 17, 2026

Neumora Therapeutics Shares Rise After William Blair Upgrade - marketscreener.com

Feb 17, 2026
pulisher
Feb 17, 2026

Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Up After Analyst Upgrade - MarketBeat

Feb 17, 2026
pulisher
Feb 17, 2026

William Blair Upgrades Neumora Therapeutics to Outperform From Market Perform - marketscreener.com

Feb 17, 2026
pulisher
Feb 17, 2026

Neumora Therapeutics (NASDAQ:NMRA) Rating Increased to Outperform at William Blair - MarketBeat

Feb 17, 2026
pulisher
Feb 15, 2026

Will Neumora Therapeutics Inc. stock go up in YEAR2025 Trading Recap & Fast Entry Momentum Trade Alerts - mfd.ru

Feb 15, 2026
pulisher
Feb 14, 2026

Neumora Therapeutics Highlights NMRA-511 AD Agitation Signal, Maps Higher-Dose Plan for 2026 - MarketBeat

Feb 14, 2026
pulisher
Feb 13, 2026

NMRA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Feb 13, 2026
pulisher
Feb 12, 2026

Neumora Therapeutics (NASDAQ:NMRA) Sets New 1-Year HighHere's What Happened - MarketBeat

Feb 12, 2026
pulisher
Feb 12, 2026

Neumora Therapeutics, Inc. (NMRA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026Slideshow (NASDAQ:NMRA) 2026-02-12 - Seeking Alpha

Feb 12, 2026
pulisher
Feb 11, 2026

NMRA: NMRA-511 shows strong efficacy in Alzheimer's agitation; pipeline and cash runway support growth - TradingView

Feb 11, 2026
pulisher
Feb 11, 2026

Differentiated NMRA-511 Efficacy and Safety in Alzheimer’s Agitation Support Buy Rating on Neumora - TipRanks

Feb 11, 2026
pulisher
Feb 11, 2026

Does Neumora Therapeutics’ (NMRA) Guggenheim Spotlight Recast Its Core Neuroscience Investment Narrative? - simplywall.st

Feb 11, 2026
pulisher
Feb 11, 2026

Neumora Therapeutics, Inc. Presents NMRA-511 Efficacy at Biotech Summit - TradingView

Feb 11, 2026
pulisher
Feb 10, 2026

Neumora Therapeutics (NASDAQ:NMRA) Trading Up 25.3%What's Next? - MarketBeat

Feb 10, 2026
pulisher
Feb 09, 2026

3 Promising Penny Stocks With Market Caps Up To $400M - simplywall.st

Feb 09, 2026
pulisher
Feb 08, 2026

Neumora gains after early-stage trial results for Alzheimer’s product - MSN

Feb 08, 2026
pulisher
Feb 06, 2026

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by Analysts - MarketBeat

Feb 06, 2026
pulisher
Feb 04, 2026

Resistance Check: Should I buy Neumora Therapeutics Inc stock nowPortfolio Update Report & Expert Verified Movement Alerts - baoquankhu1.vn

Feb 04, 2026
pulisher
Feb 04, 2026

Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times

Feb 04, 2026
pulisher
Feb 01, 2026

Short Interest in Neumora Therapeutics, Inc. (NASDAQ:NMRA) Drops By 20.2% - MarketBeat

Feb 01, 2026
pulisher
Jan 31, 2026

ETF Watch: Will Neumora Therapeutics Inc stock go up in YEAR2025 Earnings Surprises & Consistent Return Investment Signals - baoquankhu1.vn

Jan 31, 2026
pulisher
Jan 27, 2026

FY2030 Earnings Estimate for NMRA Issued By HC Wainwright - MarketBeat

Jan 27, 2026
pulisher
Jan 26, 2026

Stop Loss: Can QMMM Holdings Limited navigate macro headwindsQuarterly Market Review & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn

Jan 26, 2026
pulisher
Jan 20, 2026

Investment Review: What makes SZZLU stock attractive todayInflation Watch & Weekly High Return Forecasts - baoquankhu1.vn

Jan 20, 2026
pulisher
Jan 20, 2026

NMRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review

Jan 20, 2026
pulisher
Jan 17, 2026

Targets Report: Can AZEK continue delivering strong returnsQuarterly Profit Report & AI Based Trade Execution Alerts - baoquankhu1.vn

Jan 17, 2026
pulisher
Jan 17, 2026

Volume Report: Is Neumora Therapeutics Inc showing insider buying2025 Fundamental Recap & Weekly Return Optimization Alerts - baoquankhu1.vn

Jan 17, 2026
pulisher
Jan 16, 2026

Earnings Beat: Should I hold or sell SPCE nowMarket Weekly Review & Fast Gain Stock Trading Tips - baoquankhu1.vn

Jan 16, 2026

Neumora Therapeutics Inc Stock (NMRA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Neumora Therapeutics Inc Stock (NMRA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Pinto Joshua
President
Feb 17 '26
Sale
3.54
5,967
21,093
57,783
BERNS PAUL L
See Remarks
Feb 17 '26
Sale
3.51
9,819
34,459
7,395,185
Milligan Michael Lee
See Remarks
Feb 17 '26
Sale
3.56
1,436
5,119
21,034
$45.68
price down icon 3.69%
$53.83
price down icon 6.87%
$29.72
price up icon 0.68%
$101.95
price down icon 1.78%
$143.57
price down icon 4.21%
biotechnology ONC
$292.94
price down icon 2.03%
Cap:     |  Volume (24h):